A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
At a glance
Conditions
NCT06697184
Where you'd take part
This study runs at 17 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, Australiano site contact published
Recruiting
Cabrini Hospital Malvern
Malvern, Victoria, Australiano site contact published
Recruiting
Chu Dijon
Dijon, Franceno site contact published
Recruiting
Chu Montpellier Hopital Saint Eloi
Montpellier, Franceno site contact published
Recruiting
Dana Farber Cancer Institute
Boston, Massachusettsno site contact published
Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indianano site contact published
Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washingtonno site contact published
Recruiting
Genesiscare St Andrews
Adelaide, South Australia, Australiano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Study Director · STUDY_DIRECTOR · BeOne Medicines
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants who Experience Tumor Lysis Syndrome (TLS)Up to approximately 4 months
TLS will be defined by Howard criteria during the schedule-limiting toxicity (SLT) evaluation window